p16, COX-2, and Ki67 protein expression in DCIS and risk of ipsilateral invasive breast cancer.

IF 3.7 3区医学 Q2 ONCOLOGY

Cancer Epidemiology Biomarkers & Prevention Pub Date : 2025-04-14 DOI:10.1158/1055-9965.EPI-25-0143

Thomas E Rohan, Chenxin Zhang, Yihong Wang, Fergus J Couch, Robert T Greenlee, Stacey Honda, Azadeh Stark, Larissa L White, Dhananjay A Chitale, Xiaonan Xue, Mindy Ginsberg, Olivier Loudig

{"title":"p16, COX-2, and Ki67 protein expression in DCIS and risk of ipsilateral invasive breast cancer.","authors":"Thomas E Rohan, Chenxin Zhang, Yihong Wang, Fergus J Couch, Robert T Greenlee, Stacey Honda, Azadeh Stark, Larissa L White, Dhananjay A Chitale, Xiaonan Xue, Mindy Ginsberg, Olivier Loudig","doi":"10.1158/1055-9965.EPI-25-0143","DOIUrl":null,"url":null,"abstract":"Background: Prior research on the associations of p16, COX-2, and Ki67 immunopositivity in ductal carcinoma in situ (DCIS) tissue with risk of subsequent ipsilateral invasive breast cancer (IBC) is limited.Methods: In a case-control study nested in a cohort of women diagnosed with DCIS, immunostaining for p16, COX-2, and Ki67 was performed on DCIS tissue from those who developed subsequent ipsilateral IBC (cases; n=146) and on matched subjects who did not develop IBC (controls; n=273). Conditional logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the associations between immunopositivity for p16, COX-2, and Ki67 and risk of subsequent ipsilateral IBC.Results: There was no association between p16, COX-2, and Ki67 immunopositivity, examined either individually or in combination, with risk of ipsilateral IBC. Compared to all other groups, the multivariable OR (95% CI) for women who were triple positive for the three markers was 1.16 (0.38, 3.54).Conclusions: p16, COX-2, and Ki67 immunopositivity were not associated with altered risk of ipsilateral IBC in women with DCIS.Impact: p16, COX-2, and Ki67 may not be prognostic for ipsilateral IBC in women with DCIS.","PeriodicalId":9458,"journal":{"name":"Cancer Epidemiology Biomarkers & Prevention","volume":" ","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Epidemiology Biomarkers & Prevention","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1158/1055-9965.EPI-25-0143","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Prior research on the associations of p16, COX-2, and Ki67 immunopositivity in ductal carcinoma in situ (DCIS) tissue with risk of subsequent ipsilateral invasive breast cancer (IBC) is limited.

Methods: In a case-control study nested in a cohort of women diagnosed with DCIS, immunostaining for p16, COX-2, and Ki67 was performed on DCIS tissue from those who developed subsequent ipsilateral IBC (cases; n=146) and on matched subjects who did not develop IBC (controls; n=273). Conditional logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the associations between immunopositivity for p16, COX-2, and Ki67 and risk of subsequent ipsilateral IBC.

Results: There was no association between p16, COX-2, and Ki67 immunopositivity, examined either individually or in combination, with risk of ipsilateral IBC. Compared to all other groups, the multivariable OR (95% CI) for women who were triple positive for the three markers was 1.16 (0.38, 3.54).

Conclusions: p16, COX-2, and Ki67 immunopositivity were not associated with altered risk of ipsilateral IBC in women with DCIS.

Impact: p16, COX-2, and Ki67 may not be prognostic for ipsilateral IBC in women with DCIS.

查看原文本刊更多论文

p16、COX-2和Ki67蛋白在DCIS中的表达与同侧浸润性乳腺癌的风险

背景：先前关于导管原位癌（DCIS）组织中p16、COX-2和Ki67免疫阳性与随后同侧浸润性乳腺癌（IBC）风险之间关系的研究有限。方法：在一组确诊为DCIS的女性患者中进行病例对照研究，对随后发生同侧IBC的DCIS组织进行p16、COX-2和Ki67免疫染色(病例；n=146)和匹配的未发生IBC的受试者(对照；n = 273)。使用条件逻辑回归来估计p16、COX-2和Ki67免疫阳性与随后同侧IBC风险之间的比值比（ORs）和95%置信区间（CIs）。结果：无论是单独检查还是联合检查，p16、COX-2和Ki67免疫阳性与同侧IBC的风险之间没有关联。与所有其他组相比，三种标志物三重阳性的妇女的多变量OR （95% CI）为1.16（0.38,3.54）。结论：p16、COX-2和Ki67免疫阳性与DCIS患者患同侧IBC的风险改变无关。影响：p16、COX-2和Ki67可能不是DCIS患者同侧IBC的预后指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Epidemiology Biomarkers & Prevention 医学-公共卫生、环境卫生与职业卫生

CiteScore

6.50

自引率

2.60%

发文量

538

审稿时长

1.6 months

期刊介绍： Cancer Epidemiology, Biomarkers & Prevention publishes original peer-reviewed, population-based research on cancer etiology, prevention, surveillance, and survivorship. The following topics are of special interest: descriptive, analytical, and molecular epidemiology; biomarkers including assay development, validation, and application; chemoprevention and other types of prevention research in the context of descriptive and observational studies; the role of behavioral factors in cancer etiology and prevention; survivorship studies; risk factors; implementation science and cancer care delivery; and the science of cancer health disparities. Besides welcoming manuscripts that address individual subjects in any of the relevant disciplines, CEBP editors encourage the submission of manuscripts with a transdisciplinary approach.